Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

January 14, 2021

Study Completion Date

January 14, 2021

Conditions

Limbus CorneaeLimbus Corneae Insufficiency Syndrome

Interventions

DRUG

LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation

LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.

Trial Locations (1)

CliPS, Seoul

All Listed Sponsors

lead

CliPS Co., Ltd

INDUSTRY

NCT04773431 - Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency | Biotech Hunter | Biotech Hunter